Ipca Laboratories Receives Form 483 with 3 Observations from US FDA Inspection

The US FDA has conducted an inspection of Ipca Laboratories' Active Pharmaceutical Ingredients (APIs) manufacturing facility at Tarapur, Palghar-Maharashtra, from 18th December 2025 to 5th December 2025. At the end of the inspection, the US FDA issued a Form 483 with 3 observations. The company will submit its detailed response to these observations within the specified time and collaborate with the agency to address these issues promptly. Ipca Laboratories values quality and compliance and is committed to maintaining high standards across all its manufacturing facilities.